RxDoctor Payments Data

Andrew Ho

Interventional Cardiology · Temecula, CANPI 1801919014

Payments from drug & device makers

$72,026in general payments, 2019–2025

Across 908 payments — averaging $79.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$24K
  • Johnson & Johnson$18K
  • Abbott$10K
  • Medtronic$6K
  • Opsens Inc.$2K
  • Philips North America LLC$1K
  • plus $11K from 46 others

What the payments were for

  • Consulting fees$8251%
  • Speaking & faculty fees$44,91562%
  • Travel & lodging$4,0826%
  • Food & beverage$22,06731%
  • Education$1370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,026 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,296,886
Medicare patients
1,179
Services billed
8,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban228$299,418
XareltoRivaroxaban130$150,351
FarxigaDapagliflozin Propanediol56$72,871
EntrestoSacubitril/Valsartan60$59,342
MultaqDronedarone Hcl30$45,494
Repatha SureclickEvolocumab39$32,659
BrilintaTicagrelor31$31,204
JardianceEmpagliflozin17$22,815
Praluent PenAlirocumab23$11,243
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid88$10,721
VascepaIcosapent Ethyl25$10,349
Ranolazine ErRanolazine101$10,296
Repatha SyringeEvolocumab13$6,930
Metoprolol Succinate429$6,725
Amiodarone Hcl82$5,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$378$299,418228 claims
Johnson & JohnsonXarelto$17,808$150,351130 claims
AstraZenecaFarxiga, Brilinta$23,980$104,07587 claims
NovartisEntresto$1,105$59,34260 claims
Sanofi-aventis U.S. LLCMultaq$398$45,49430 claims
Boehringer IngelheimJardiance$564$22,81517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →